{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:41:49Z","timestamp":1760550109247},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1985,4,1]],"date-time":"1985-04-01T00:00:00Z","timestamp":481161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[1985,4]]},"DOI":"10.1016\/s0016-5085(85)80002-0","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T14:39:23Z","timestamp":1471012763000},"page":"870-880","source":"Crossref","is-referenced-by-count":78,"title":["Recombinant Leukocyte A Interferon Treatment in Patients With Chronic Hepatitis B Virus Infection"],"prefix":"10.1016","volume":"88","author":[{"given":"Masao","family":"Omata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Imazeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Yokosuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuo","family":"Uchiumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunio","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0016-5085(85)80002-0_bib1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/284316a0","article-title":"Synthesis in E. coli of a polypeptide with human leucocyte interferon activity","volume":"284","author":"Nagatq","year":"1980","journal-title":"Nature"},{"key":"10.1016\/S0016-5085(85)80002-0_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/287411a0","article-title":"Human leucocyte interferon produced by E. coli is biologically active","volume":"287","author":"Goeddel","year":"1980","journal-title":"Nature"},{"key":"10.1016\/S0016-5085(85)80002-0_bib3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-96-5-549","article-title":"Recombinant leucocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effect in cancer patients","volume":"96","author":"Gutterman","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0016-5085(85)80002-0_bib4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM197609022951001","article-title":"Effect of human leucocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis","volume":"295","author":"Greenberg","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/S0016-5085(85)80002-0_bib5","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1073\/pnas.77.12.7010","article-title":"Construction and identification of bacterial plasmids containing nucleotide sequence for human leucocyte interferon","volume":"77","author":"Maeda","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0016-5085(85)80002-0_bib6","doi-asserted-by":"crossref","first-page":"9750","DOI":"10.1016\/S0021-9258(19)68827-7","article-title":"Purification and characterization of recombinant human leucocyte interferon (IFLrA) with monoclonal antibodies","volume":"256","author":"Staehelin","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1016\/S0016-5085(85)80002-0_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00000441-197507000-00021","article-title":"DNA and DNA polymerase in the core of the Dane particles of hepatitis B","volume":"270","author":"Robinson","year":"1975","journal-title":"Am J Med SO"},{"key":"10.1016\/S0016-5085(85)80002-0_bib8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1128\/jvi.36.3.829-836.1980","article-title":"Virus of pekin ducks with structural and biological relatedness to human hepatitis B virus","volume":"36","author":"Mason","year":"1980","journal-title":"J Virol"},{"key":"10.1016\/S0016-5085(85)80002-0_bib9","series-title":"The clinical potential of interferons","first-page":"299","article-title":"Potency standardization of human interferon preparations for clinical trials","author":"Kohase","year":"1982"},{"key":"10.1016\/S0016-5085(85)80002-0_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0140-6736(83)91737-3","article-title":"Antibodies to human leucocyte interferon in cancer patients","volume":"i","author":"Trown","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/S0016-5085(85)80002-0_bib11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(80)90885-5","article-title":"Double-blind study of leucocyte interferon administration in chronic HBsAg-positive hepatitis","volume":"i","author":"Weimar","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/S0016-5085(85)80002-0_bib12","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/143.6.772","article-title":"Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside","volume":"143","author":"Scullard","year":"1981","journal-title":"J Infect Dis"},{"key":"10.1016\/S0016-5085(85)80002-0_bib13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1099\/0022-1317-39-3-541","article-title":"Large scale production of human leucocyte interferon containing 10 units per ml","volume":"39","author":"Cantell","year":"1978","journal-title":"J Gen Virol"},{"key":"10.1016\/S0016-5085(85)80002-0_bib14","first-page":"162","article-title":"A phase 1 trial of twice daily recombinant human leucocyte A interferon (IFLrA) in cancer patients (abstr)","author":"Leavitt","year":"1982","journal-title":"Am Soc Clin Onc"},{"key":"10.1016\/S0016-5085(85)80002-0_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1128\/AAC.21.1.93","article-title":"Antiviral treatment of chronic hepatitis B virus infection. 4. Pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination","volume":"21","author":"Sacks","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/S0016-5085(85)80002-0_bib16","first-page":"277","article-title":"Effects of human leucocyte interferon on hepatitis B virus replication and immune response in patients with chronic hepatitis B infection","volume":"1","author":"Scullard","year":"1979","journal-title":"J Clin Lab Immunol"},{"key":"10.1016\/S0016-5085(85)80002-0_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gut.19.2.91","article-title":"Treatment of HBsAg-positive chronic active hepatitis with human fibroblast interferon","volume":"19","author":"Kingham","year":"1978","journal-title":"Gut"},{"key":"10.1016\/S0016-5085(85)80002-0_bib18","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1073\/pnas.78.3.1848","article-title":"Production of hybridomas secreting monoclonal antibodies to the human leucocyte interferons","volume":"78","author":"Staehclin","year":"1981","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0016-5085(85)80002-0_bib19","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(76)92460-0","article-title":"Administration of human fibroblast interferon in chronic hepatitis B infection","volume":"ii","author":"Desmyter","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/S0016-5085(85)80002-0_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/inf.1980.12.issue-3.13","article-title":"Interferon treatment in acute hepatitis B infection with prolonged course","volume":"12","author":"Iwarson","year":"1980","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/S0016-5085(85)80002-0_bib21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0002-9343(79)90088-3","article-title":"Fibroblast interferon treatment of a patient with chronic active hepatitis","volume":"67","author":"Dolen","year":"1979","journal-title":"Am J Med"},{"key":"10.1016\/S0016-5085(85)80002-0_bib22","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/infdis\/148.5.907","article-title":"Acute Dane particle suppression with recombinant leucocyte A interferon in chronic hepatitis B virus infection","volume":"148","author":"Smith","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1016\/S0016-5085(85)80002-0_bib23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(80)90442-0","article-title":"Serum levels of hepatitis surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis","volume":"ii","author":"Sagnelli","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/S0016-5085(85)80002-0_bib24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0016-5085(81)80002-9","article-title":"Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B","volume":"81","author":"Scullard","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1016\/S0016-5085(85)80002-0_bib25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/0003-4819-96-4-447","article-title":"Reactivation of chronic hepatitis B virus infection by cancer chemotherapy","volume":"96","author":"Hoofnagle","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0016-5085(85)80002-0_bib26","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0016-5085(83)90197-X","article-title":"Effect of short-term prednisone therapy on aminotransferase levels and hepatitis B virus markers in chronic type B hepatitis","volume":"84","author":"Rakela","year":"1983","journal-title":"Gastroenterology"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508585800020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508585800020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T22:03:14Z","timestamp":1657058594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508585800020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1985,4]]}},"alternative-id":["S0016508585800020"],"URL":"https:\/\/doi.org\/10.1016\/s0016-5085(85)80002-0","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[1985,4]]}}}